No profile data available.
SanBio Company Limited (4592.T) is a healthcare company in the brain and nerve treatment drugs industry, based in Tokyo, Japan, with about 33 full-time employees.
It reported revenue of 0 JPY for fiscal year 2026, and net income of -3.84 billion JPY. Its market capitalization was 79.54 billion JPY as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended January 31, 2026; market data as of October 9, 2026.
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury.
SanBio reported 0 JPY in revenue for fiscal year 2026.
79.54 billion JPY as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Oncolys BioPharma Inc. (4588.T), K Pharma,Inc. (4896.T), Kringle Pharma, Inc. (4884.T), MedRx Co., Ltd (4586.T).